| CAS: | 1998197-39-9 | |||||
| 分子式: | C21H18N2O2S | |||||
| 分子量: | 362.44 | |||||
| 英文名称: |
|
| 货号 | 品牌 | 产品名称 | 规格 | 包装、参考价格 | |||||||||||||||||||||||||||||
| H995102 | MACKLIN | 6-methyl-3-(2-nitro-1-(thiophen-2-yl)ethyl)-2-phenyl-1H-indole | ≥95% | 1458元/5mg; | 咨询 | ||||||||||||||||||||||||||||
储存：室温 | |||||||||||||||||||||||||||||||||
| SML2710 | Sigma-Aldrich | ZCZ011 | ≥98% (HPLC) | 941.43元/5 MG; 3793.48元/25 MG; | 咨询 | ||||||||||||||||||||||||||||
产品说明 生化/生理作用 ZCZ011 is a brain-penetrant, cannabinoid receptor CB1-selective positive allosteric modulator (PAM) that enhances orthosteric agonist CP55,940, while reduces orthosteric inverse agonist SR141716A, CB1 binding. ZCZ011 potentiates AEA-stimulated GTPγS binding (Emax = 46.5% without vs. 115.2% with 100 nM ZCZ011; mouse brain membranes) and cellular signaling (β-arrestin Emax = 100% without vs.157% with 100 nM ZCZ011, pERK pIC50 = 6.5 without vs. 8.3 with 10 nM ZCZ011; hCB1 cells). ZCZ011 exhibits antinociceptive efficay in murine chronic constriction injury (CCI) model of neuropathic pain & carrageenan model of inflammatory pain (40 mg/kg i.p.) without cannabimimetic side-effects. 基本信息
产品性质
安全信息
| |||||||||||||||||||||||||||||||||
m.cnreagent.com